Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction-associated steatotic liver disease - PubMed (original) (raw)

. 2024 Nov;54(11):e14279.

doi: 10.1111/eci.14279. Epub 2024 Jun 28.

Elena Cristina Rusu 2, Helena Clavero-Mestres 2, Andrea Barrientos-Riosalido 2, Laia Bertran 2, Razieh Mahmoudian 2, Carmen Aguilar 2, David Riesco 2 3, Javier Ugarte Chicote 2 4, David Parada 2 5, Salomé Martínez 2 4, Fàtima Sabench 2 6, Cristóbal Richart 2, Teresa Auguet 2 3

Affiliations

Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction-associated steatotic liver disease

Carmen Arto et al. Eur J Clin Invest. 2024 Nov.

Abstract

Background and aims: The rise in obesity highlights the need for improved therapeutic strategies, particularly in addressing metabolic dysfunction-associated steatotic liver disease (MASLD). We aim to assess the role of tryptophan metabolic pathways in the pathogenesis of obesity and in the different histological stages of MASLD.

Materials and methods: We used ultra-high performance liquid chromatography to quantify circulating levels of 15 tryptophan-related metabolites from the kynurenine, indole and serotonin pathways. A cohort of 76 subjects was analysed, comprising 18 subjects with normal weight and 58 with morbid obesity, these last being subclassified into normal liver (NL), simple steatosis (SS) and metabolic dysfunction-associated steatohepatitis (MASH). Then, we conducted gene expression analysis of hepatic IDO-1 and kynyrenine-3-monooxygenase (KMO).

Results: Key findings in obesity revealed a distinct metabolic signature characterized by a higher concentration of different kynurenine-related metabolites, a decrease in indole-3-acetic acid and indole-3-propionic acid, and an alteration in the serotonin pathway. Elevated tryptophan levels were associated with MASLD presence (37.659 (32.577-39.823) μM of tryptophan in NL subjects; 41.522 (38.803-45.276) μM in patients with MASLD). Overall, pathway fluxes demonstrated an induction of tryptophan catabolism via the serotonin pathway in SS subjects and into the kynurenine pathway in MASH. We found decreased IDO-1 and KMO hepatic expression in NL compared to SS.

Conclusions: We identified a distinctive metabolic signature in obesity marked by changes in tryptophan catabolic pathways, discernible through altered metabolite profiles. We observed stage-specific alterations in tryptophan catabolism fluxes in MASLD, highlighting the potential utility of targeting these pathways in therapeutic interventions.

Keywords: kynurenine; metabolic dysfunction‐associated steatotic liver disease; serotonin; tryptophan.

© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

PubMed Disclaimer

References

REFERENCES

    1. Mayoral LPC, Andrade GM, Mayoral EPC, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020;151(1):11‐21.
    1. Wang Y, Zhao L, Gao L, Pan A, Xue H. Health policy and public health implications of obesity in China. Lancet Diabetes Endocrinol. 2021;9(7):446‐461.
    1. Green CR, Wallace M, Divakaruni AS, et al. Branched‐chain amino acid catabolism fuels adipocyte differentiation and lipogenesis. Nat Chem Biol. 2016;12(1):15‐21.
    1. Solon‐Biet SM, Cogger VC, Pulpitel T, et al. Branched‐chain amino acids impact health and lifespan indirectly via amino acid balance and appetite control. Nat Metab. 2019;1(5):532‐545.
    1. Laurans L, Venteclef N, Haddad Y, et al. Genetic deficiency of indoleamine 2,3‐dioxygenase promotes gut microbiota‐mediated metabolic health. Nat Med. 2018;24(8):1113‐1120.

MeSH terms

Substances

LinkOut - more resources